ZLAB News and Press, Zai Lab Limited From 05/22/25

2025-05-22 11:25:21 ET Summary Zai Lab Limited has shown positive momentum since my last update, signaling a more optimistic outlook for the company. ZLAB received Fast Track designation from the U.S. FDA, highlighting progress in its pipeline and regulatory milestones. Recent...

2025-05-21 18:43:20 ET Summary NovoCure Limited beat Q1 expectations and highlighted some positive pipeline updates, but NVCR shares remain well below recent highs. Analysts remain bullish, with multiple Buy ratings and price targets in the $33–$38 range, despite some ongoi...

2025-05-20 09:10:00 ET Summary The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%. Positioning in biotechnology weighed on relative returns, while an underweight to life sciences tools and services contributed to performance. Despite ne...

2025-05-19 13:13:00 ET Summary The Fund returned 5.20% and the MSCI All Country World ex USA Index returned 5.23%. Stock selection in the consumer discretionary sector detracted from relative performance. Stock selection in the financials sector contributed. We will seek to us...

2025-05-19 09:09:28 ET More on Zai Lab Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks Zai Lab...

- The Company is on track to initiate a pivotal study for ZL-1310 in small cell lung cancer (SCLC) in 2025 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Company’s potenti...

2025-05-11 08:55:31 ET Zai Lab Limited (ZLAB) Q1 2025 Earnings Conference Call May 08, 2025, 08:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - ...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

2025-05-08 06:04:57 ET More on Zai Lab Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript Zai Lab...

– Total revenues grew 22% y-o-y to $106.5 million for the first quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million – Operating loss improved significantly, declining 20% year-over-year to $56.3 million for the first quarter of ...